Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Amphastar Pharmaceuticals (AMPH) Enterprise Value: 2013-2025

Historic Enterprise Value for Amphastar Pharmaceuticals (AMPH) over the last 13 years, with Sep 2025 value amounting to $962.9 million.

  • Amphastar Pharmaceuticals' Enterprise Value fell 54.40% to $962.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $272.6 million, marking a year-over-year decrease of 79.77%. This contributed to the annual value of $1.6 billion for FY2024, which is 42.22% down from last year.
  • Latest data reveals that Amphastar Pharmaceuticals reported Enterprise Value of $962.9 million as of Q3 2025, which was up 13.21% from $850.6 million recorded in Q2 2025.
  • Over the past 5 years, Amphastar Pharmaceuticals' Enterprise Value peaked at $2.7 billion during Q4 2023, and registered a low of $798.5 million during Q3 2021.
  • Over the past 3 years, Amphastar Pharmaceuticals' median Enterprise Value value was $1.7 billion (recorded in 2024), while the average stood at $1.7 billion.
  • In the last 5 years, Amphastar Pharmaceuticals' Enterprise Value spiked by 129.64% in 2023 and then tumbled by 54.40% in 2025.
  • Amphastar Pharmaceuticals' Enterprise Value (Quarterly) stood at $977.7 million in 2021, then climbed by 20.53% to $1.2 billion in 2022, then spiked by 129.64% to $2.7 billion in 2023, then tumbled by 42.22% to $1.6 billion in 2024, then crashed by 54.40% to $962.9 million in 2025.
  • Its Enterprise Value was $962.9 million in Q3 2025, compared to $850.6 million in Q2 2025 and $1.1 billion in Q1 2025.